



BRIAN SANDOVAL
Governor

STATE OF NEVADA
DEPARTMENT OF HEALTH AND HUMAN SERVICES
DIVISION OF HEALTH CARE FINANCING AND POLICY
1100 E. William Street, Suite 101
Carson City, Nevada 89701
www.dhcfp.nv.gov

ROMAINE GILLILAND
Director
LAURIE SQUARTSOFF
Administrator

NOTICE OF OPEN PUBLIC MEETING

The Division of Health Care Financing and Policy (DHCFP) Pharmacy and Therapeutics Committee will conduct a public meeting on **November 13, 2014**, beginning at **1:00 p.m.** at the following location:

JW Marriott Las Vegas Resort and Spa
Grand Ballroom A
221 N. Rampart Blvd
Las Vegas, NV 89145
702-869-7777

This meeting will be held only in Las Vegas, NV, there will be no teleconference to Carson City, NV.

Reasonable efforts will be made to assist and accommodate physically challenged persons desiring to attend the meeting. Please call Rita Mackie at: 775-684-3681 or email rmackie@dhcfp.nv.gov in advance, but no later than two working days prior to the meeting, so that arrangements may be conveniently made.

Items may be taken out of order.

Items may be combined for consideration by the public body.

Items may be pulled or removed from the agenda at any time.

Public comment is limited to 5 minutes per individual, organization, or agency, but may be extended at the discretion of the Chairperson.

AGENDA

- I. CALL TO ORDER AND ROLL CALL
- II. PUBLIC COMMENT

No action may be taken on a matter raised under this item of the agenda until the matter itself has been specifically included on the agenda as an item upon which action can be taken.

- III. **FOR POSSIBLE ACTION:** Review and Approval of the June 26, 2014 Meeting Minutes

IV. STATUS UPDATE BY DHCFP

- A. Public Comment
- B. Program Updates

V. ANNUAL REVIEW - ESTABLISHED DRUG CLASSES

A. CENTRAL NERVOUS SYSTEM: ADHD/STIMULANTS

- 1. Public Comment
- 2. Drug Class Review Presentation – Catamaran
- 3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
- 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy
- 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

B. ANTIBIOTICS: Cephalosporins 3rd Generation

- 1. Public Comment
- 2. Drug Class Review Presentation – Catamaran
- 3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
- 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy
- 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

C. ANTICOAGULANTS: Injectable

- 1. Public Comment
- 2. Drug Class Review Presentation – Catamaran
- 3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
- 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy
- 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

- D. ANTI-MIGRAINE AGENTS: Triptans
1. Public Comment
 2. Drug Class Review Presentation – Catamaran
 3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- E. BENIGN PROSTATIC HYPERPLASIA (BPH) AGENTS: 5-alpha-reductase Inhibitors
1. Public Comment
 2. Drug Class Review Presentation – Catamaran
 3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- F. CARDIOVASCULAR: Antihyperlipidemics, Triglyceride Lowering Agents
1. Public Comment
 2. Drug Class Review Presentation – Catamaran
 3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- G. DIABETIC AGENTS: DPP-4 Inhibitors and Combinations
1. Public Comment
 2. Drug Class Review Presentation – Catamaran
 3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy

5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- H. ELECTROLYTE DEPLETERS
1. Public Comment
 2. Drug Class Review Presentation – Catamaran
 3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- I. OPHTHALMIC ANTIHISTAMINES
1. Public Comment
 2. Drug Class Review Presentation – Catamaran
 3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- J. PSORIASIS AGENTS: Topical
1. Public Comment
 2. Drug Class Review Presentation – Catamaran
 3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- K. BONE OSSIFICATION AGENTS: BISPHOSPHONATES
1. Public Comment
 2. Drug Class Review Presentation – Catamaran
 3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class

- b) Identify Exclusions/Exceptions for Certain Patient Groups
- 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy
- 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

L. ANTIDEPRESSANTS: SSRI

- 1. Public Comment
- 2. Drug Class Review Presentation – Catamaran
- 3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
- 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy
- 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

M. ANTIDEPRESSANTS: OTHER

- 1. Public Comment
- 2. Drug Class Review Presentation – Catamaran
- 3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
- 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy
- 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

VI. ANNUAL REVIEW - ESTABLISHED DRUG CLASSES BEING REVIEWED DUE TO THE RELEASE OF NEW DRUGS.

N. ANALGESICS: LONG ACTING NARCOTICS

- 1. Public Comment
- 2. Drug Class Review Presentation – Catamaran
- 3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
- 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy

5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- O. Diabetic Agents: GLP-1
1. Public Comment
 2. Drug Class Review Presentation – Catamaran
 3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- P. DIABETIC AGENTS: INCRETIN MIMETICS
1. Public Comment
 2. Drug Class Review Presentation – Catamaran
 3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- Q. CARDIOVASCULAR: ANTIHYPERLIPIDEMICS, NIACIN AGENTS
1. Public Comment
 2. Drug Class Review Presentation – Catamaran
 3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- R. CENTRAL NERVOUS SYSTEM: Oral Anticonvulsants, Misc.
1. Public Comment
 2. Drug Class Review Presentation – Catamaran
 3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups

4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- S. ANDROGENIC AGENTS: Topical
1. Public Comment
 2. Drug Class Review Presentation – Catamaran
 3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- T. IMMUNOMODULATORS: Injectable
1. Public Comment
 2. Drug Class Review Presentation – Catamaran
 3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- U. PLATELET AGGREGATION INHIBITORS
1. Public Comment
 2. Drug Class Review Presentation – Catamaran
 3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- V. RESPIRATORY: INHALED ANTICHOLINERGIC AGENTS
1. Public Comment
 2. Drug Class Review Presentation – Catamaran
 3. **For Possible Action:** Committee Discussion and Action

- a) Approve Clinical/Therapeutic Equivalency of Agents in Class
- b) Identify Exclusions/Exceptions for Certain Patient Groups
- 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy
- 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

W. RESPIRATORY: LONG ACTING BETA ADRENERGICS

- 1. Public Comment
- 2. Drug Class Review Presentation – Catamaran
- 3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
- 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy
- 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

X. ANTIVIRALS: Hepatitis C Ribavirins

- 1. Public Comment
- 2. Drug Class Review Presentation – Catamaran
- 3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
- 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy
- 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

VII. ANNUAL REVIEW – DRUG CLASSES WITHOUT PROPOSED CHANGES

- A. Public Comment
- B. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy without Changes
- C. **For Possible Action:** Committee Discussion and Action
 - 1. ACNE AGENTS: Topical, Retinoid Agents and Combinations
 - 2. ACNE AGENTS: Topical, Benzoyl Peroxide, Antibiotics and Combination Products
 - 3. ALZHEIMER'S AGENTS

4. ANALGESICS/ANESTHETICS: Topical
5. ANALGESICS: Tramadol and Related Drugs
6. ANAPHYLAXIS: Self-Injectable Epinephrine
7. ANTIBIOTICS: Cephalosporins 2nd Generation
8. ANTIBIOTICS: Macrolides
9. ANTIBIOTICS: Quinolones 2nd Generation
10. ANTIBIOTICS: Quinolones 3rd Generation
11. ANTICOAGULANTS: Oral
12. ANTIEMETICS: Oral, 5-HT₃s
13. ANTIFUNGALS: Onychomycosis Agents
14. ANTIHISTAMINES: 2nd Generation
15. ANTIHYPERURICEMICS: Xanthine Oxidase Inhibitors for Gout
16. ANTIPARKINSON'S AGENTS: Non-ergot Dopamine Agonists
17. ANTIPSYCHOTICS: Oral, Atypical
18. ANTIVIRAL AGENTS: Influenza
19. BENIGN PROSTATIC HYPERPLASIA (BPH) AGENTS: Alpha-blockers
20. CARDIOVASCULAR: ACE Inhibitors and Diuretic Combinations
21. CARDIOVASCULAR: Angiotensin II Receptor Blockers and Diuretic Combinations
22. CARDIOVASCULAR: Antihyperlipidemics, Bile Acid Sequestrants
23. CARDIOVASCULAR: Antihyperlipidemics, Cholesterol Absorption Inhibitors
24. CARDIOVASCULAR: Antihyperlipidemics, Statins and Statin Combinations
25. CARDIOVASCULAR: Beta blockers
26. CARDIOVASCULAR: Calcium Channel Blockers and Combinations
27. CARDIOVASCULAR: Direct Renin Inhibitors and Combinations
28. CENTRAL NERVOUS SYSTEM: Anticonvulsants, Barbiturates
29. CENTRAL NERVOUS SYSTEM: Anticonvulsants, Benzodiazepines
30. CENTRAL NERVOUS SYSTEM: Oral Anticonvulsants, Hydantoins
31. CENTRAL NERVOUS SYSTEM: Sedative Hypnotics
32. DIABETIC AGENTS: Biguanides
33. DIABETIC AGENTS: Insulin Products
34. DIABETIC AGENTS: Meglitinides and Combinations
35. DIABETIC AGENTS: Other Agents
36. DIABETIC AGENTS: Sulfonylureas
37. DIABETIC AGENTS: Thiazolidinediones
38. ERYTHROPOIESIS STIMULATING PROTEINS
39. FIBROMYALGIA AGENTS
40. GASTROINTESTINAL AGENTS: H₂RAs
41. GASTROINTESTINAL AGENTS: Pancreatic Enzymes
42. GASTROINTESTINAL AGENTS: PPIs
43. GASTROINTESTINAL AGENTS: Ulcerative Colitis
44. GROWTH HORMONE AGENTS

45. Antivirals: Hepatitis C Pegylated Interferons
46. Antivirals: Hepatitis C Polymerase Inhibitors
47. Antivirals: Hepatitis C Protease Inhibitors
48. HERPETIC ANTIVIRAL AGENTS
49. HERPETIC ANTIVIRAL AGENTS: Topical
50. IMMUNOMODULATORS: Topical
51. IMPETIGO AGENTS: Topical
52. LEUKOTRIENE MODIFIERS
53. MULTIPLE SCLEROSIS AGENTS: Injectable Disease Modifying
54. MULTIPLE SCLEROSIS AGENTS: Oral Disease Modifying (NEW)
55. MULTIPLE SCLEROSIS AGENTS: Specific Symptomatic Treatment
56. NASAL CALCITONINS
57. NEUROPATHIC PAIN AGENTS
58. OPHTHALMIC ANTIBIOTICS: Macrolides
59. OPHTHALMIC GLAUCOMA AGENTS
60. OPHTHALMIC GLAUCOMA AGENTS: PROSTAGLANDINS
61. OPHTHALMIC NON-STEROIDAL ANTI-INFLAMMATORY AGENTS
62. OPHTHALMIC QUINOLONES
63. OPHTHALMIC STEROIDS
64. OTIC FLUOROQUINOLONES
65. PEDICULOCIDES / SCABICIDES
66. PROGESTINS FOR CACHEXIA
67. PULMONARY ARTERIAL HYPERTENSION AGENTS: Inhaled Agents
68. PULMONARY ARTERIAL HYPERTENSION: Oral Agents
69. RESPIRATORY: ORAL COPD AGENTS
70. RESPIRATORY: Inhaled Corticosteroid/Beta- Adrenergic Combinations
71. RESPIRATORY: Inhaled Corticosteroids/Nebs
72. RESPIRATORY: Intranasal Rhinitis Agents
73. RESPIRATORY: Intranasal Steroid
74. RESPIRATORY: Short Acting Beta Adrenergics-Inhalers/Nebs
75. RESTLESS LEG SYNDROME AGENTS
76. SKELETAL MUSCLE RELAXANTS
77. URINARY TRACT ANTISPASMODICS

VIII. REPORT BY CATAMARAN ON NEW DRUGS TO MARKET, NEW GENERIC DRUGS TO MARKET, AND NEW LINE EXTENSIONS

- IX. REVIEW OF NEXT MEETING LOCATION, DATE, AND TIME
 - A. March 26, 2015
- X. PUBLIC COMMENT
- XI. ADJOURNMENT

This notice and agenda has been posted on or before 9:00 a.m. on the third working day before the meeting at the following locations:

Notice of this meeting will be available on or after the posting date of this Agenda at the DHCFP Web site (www.dhcfp.nv.gov)

Posting of the Agenda will be at the Nevada Medicaid Central offices in Carson City and Las Vegas; Nevada State Library; Carson City Library; Churchill County Library; Las Vegas Library; Douglas County Library; Elko County Library; Lincoln County Library; Lyon County Library; Mineral County Library; Tonopah Public Library; Pershing County Library; Goldfield Public Library; Eureka Branch Library; Humboldt County Library; Lander County Library; Storey County Library; Washoe County Library; and White Pine County Library and may be reviewed during normal business hours.

If requested in writing, a copy of the action items will be mailed to you or they may be reviewed Monday through Friday from 9:00 a.m. until 5:00 p.m., or at the meeting. Please call at least one day ahead for an appointment for document review. Written comments on the proposed changes may be sent to the DHCFP, 1100 E. William Street, Suite 102, Carson City, NV 89701.

All persons that have requested in writing to receive the Open Meeting Agenda have been duly notified by mail or e-mail.

Anyone presenting documents for consideration during the public comment portion of the meeting must provide sufficient copies for each member of the committee and the official record. Copies are to be distributed at the time of the meeting and should be provided at both meeting locations; DHCFP or its contractor will not distribute public comment information or materials prior to the public meeting.